A retrospective chart review was performed for 71 eyes of 67 patients with neovascular age-related macular degeneration (AMD) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections using a treat-extend-stop protocol. The protocol consisted of an initial series of three anti-VEGF injections at 4- to 6-week intervals. If, after this initial series, the macula was found to be without fluid, then the treatment was extended by 1- to 2-week intervals until a 12-week interval between injections was achieved. Patients then received two injections at 12-week intervals. If the macula remained dry, the treatments were suspended, and patients were monitored at 4-week intervals. Monitoring was extended by 2 weeks until the interval was 12 weeks. At that time, patients were monitored quarterly for signs of recurrence. If a patient developed new fluid or had worsening visual acuity related to their AMD, the interval was decreased, or they were initiated on a different anti-VEGF agent.